Potential role of soluble CD40 ligand as inflammatory biomarker in colorectal cancer patients

International Journal of Biological Markers

Volumn 29, Issue 3, 2014, Pages e261-e267

  Dymicka Piekarska, Violetta ^a   Korniluk, Aleksandra ^a   Gryko, Mariusz ^a   Siergiejko, Elzbieta ^a   Kemona, Halina ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Adhesion molecules; Biomarker; CD40 ligand; Colorectal cancer; Platelet activation

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; PADGEM PROTEIN; VASCULAR CELL ADHESION MOLECULE 1; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CLINICAL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; THROMBOCYTE COUNT; BLOOD; COLORECTAL TUMOR; INFLAMMATION; METASTASIS; MIDDLE AGED; PATHOLOGY; THROMBOCYTE ACTIVATION;

AGED; BIOMARKERS, TUMOR; CD40 LIGAND; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM METASTASIS; P-SELECTIN; PLATELET ACTIVATION;

EID: 84907537400     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/jbm.5000083     Document Type: Article

References (34)

1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140(6): 883-899.
2. Wagner DD. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2005; 25(7): 1321-1324.
3. Henn V, Slupsky JR, Gräfe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998; 391(6667): 591-594.
4. Blumberg N, Spinelli SL, Francis CW, Taubman MB, Phipps RP. The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunol Res. 2009; 45(2-3): 251-260.
5. Danese S, Fiocchi C. Platelet activation and the CD40/ CD40 ligand pathway: mechanisms and implications for human disease. Crit Rev Immunol. 2005; 25(2): 103-121.
6. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation. 2003; 107(8): 1123-1128.
7. Ferroni P, Santilli F, Guadagni F, Basili S, Davì G. Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis. Curr Med Chem. 2007; 14(20): 2170-2180.
8. André P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a β3 integrin—dependent mechanism. Nat Med. 2002; 8(3): 247-252.
9. Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside- in signaling. Proc Natl Acad Sci USA. 2003; 100(21): 12367-12371.
10. Dallman C, Johnson PW, Packham G. Differential regulation of cell survival by CD 40. Apoptosis. 2003; 8(1): 45-53.
11. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004; 22(1): 307-328.
12. Schönbeck U, Mach F, Sukhova GK, et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res. 1997; 81(3): 448-454.
13. Lutgens E, Lievens D, Beckers L, Donners M, Daemen M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med. 2007; 17(4): 118-123.
14. Hollenbaugh D, Mischel-Petty N, Edwards CP, et al. Expression of functional CD40 by vascular endothelial cells. J Exp Med. 1995; 182(1): 33-40.
15. Laman JD, Claassen E, Noelle RJ. Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol. 1996; 16(1): 59-108.
16. Danese S, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol. 2004; 172(4): 2011-2015.
17. Huang J, Jochems C, Talaie T, et al. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood. 2012; 120(15): 3030-3038.
18. Georgopoulos NT, Merrick A, Scott N, Selby PJ, Melcher A, Trejdosiewicz LK. CD40-mediated death and cytokine secretion in colorectal cancer: a potential target for inflammatory tumour cell killing. Int J Cancer. 2007; 121(6): 1373-1381.
19. Ottaiano A, Pisano C, De Chiara A, et al. CD40 activation as potential tool in malignant neoplasms. Tumori. 2002; 88(5): 361-366.
20. Bergmann S, Pandolfi PP. Giving blood: a new role for CD40 in tumorigenesis. J Exp Med. 2006; 203(11): 2409-2412.
21. Melter M, Reinders ME, Sho M, et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood. 2000; 96(12): 3801-3808.
22. Bereznaya NM, Chekhun VF. Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy. Exp Oncol. 2007; 29(1): 2-12.
23. Elzey BD, Sprague DL, Ratliff TL. The emerging role of platelets in adaptive immunity. Cell Immunol. 2005; 238(1): 1-9.
24. Ivandic BT, Spanuth E, Haase D, Lestin HG, Katus HA. Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem. 2007; 53(7): 1231-1234.
25. Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes. 2006; 55(1): 202-208.
26. Santilli F, Basili S, Ferroni P, Davì G. CD40/CD40L system and vascular disease. Intern Emerg Med. 2007; 2(4): 256-268.
27. Roselli M, Mineo TC, Basili S, et al. Soluble CD40 ligand plasma levels in lung cancer. Clin Cancer Res. 2004; 10(2): 610-614.
28. Li R, Chen WC, Pang XQ, Hua C, Li L, Zhang XG. Expression of CD40 and CD40L in gastric cancer tissue and its clinical significance. Int J Mol Sci. 2009; 10(9): 3900-3917.
29. Tsirakis G, Pappa CA, Psarakis FE, et al. Serum concentrations and clinical significance of soluble CD40 ligand in patients with multiple myeloma. Med Oncol. 2012; 29(4): 2396-2401.
30. Jablonska E, Kiersnowska-Rogowska B, Rogowski F, Parfienczyk A, Puzewska W, Bukin M. TNF family molecules in the serum of patients with B-cell chronic lymphocytic leukemia (B-CLL). Leuk Lymphoma. 2005; 46(9): 1307-1312.
31. Dymicka-Piekarska V, Kemona H. Does colorectal cancer clinical advancement affect adhesion molecules (sP-selectin, sE-selectin and ICAM-1) concentration? Thromb Res. 2009; 124(1): 80-83.
32. Mach F, Schönbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA. 1997; 94(5): 1931-1936.
33. Loskog A, Tötterman TH. CD40L - a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets. 2007; 7(1): 23-28.
34. Dymicka-Piekarska V, Guzinska-Ustymowicz K, Kuklinski A, Kemona H. Prognostic significance of adhesion molecules (sICAM-1, sVCAM-1) and VEGF in colorectal cancer patients. Thromb Res. 2012; 129(4): e47-e50.